Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer

Clinical Breast Cancer

Volumn 16, Issue 1, 2016, Pages 59-62

  Rutter, Charles E ^a   Yao, Xiaopan ^a   Mancini, Brandon R ^a   Aminawung, Jenerius A ^a   Chagpar, Anees B ^a   Saglam, Ozlen ^a   Hofstatter, Erin W ^a   Abu Khalaf, Maysa ^a   Gross, Cary P ^a   Evans, Suzanne B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Chemotherapy; Oncotype; Recurrence; Score

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT;

21 GENE RECURRENCE SCORE ASSAY; ADULT; AGED; ARTICLE; ASSAY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; ONCOTYPE DX ASSAY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 84959854338     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.09.008     Document Type: Article

References (15)

1. S. Paik, S. Shak, G. Tang, and et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
2. S. Paik, G. Tang, S. Shak, and et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 2006 3726 3734
3. National Comprehensive Cancer Network. National Comprehensive Cancer Network Practice Guidelines in Oncology. Breast Cancer, version 3.2014. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed: September 14, 2014.
4. S.M. Stemmer, S.H. Klang, N. Ben-Baruch, and et al. The impact of the 21-gene recurrence score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients Breast Cancer Res Treat 140 2013 83 92
5. J.E. Joh, N.N. Esposito, J.V. Kiluk, and et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists Oncologist 16 2011 1520 1526
6. J. Asad, A.F. Jacobson, A. Estabrook, and et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196 2008 527 529
7. E.P. Mamounas, G. Tang, B. Fisher, and et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 J Clin Oncol 28 2010 1677 1683
8. L.A. Habel, S. Shak, M.K. Jacobs, and et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 2006 R25
9. J.F. Partin, and E.P. Mamounas Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer Ann Surg Oncol 18 2011 3399 3406
10. C. Chen, R. Dhanda, W.Y. Tseng, and et al. Evaluating use characteristics for the Oncotype Dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer J Oncol Pract 9 2013 182 187
11. W. Eiermann, M. Rezai, S. Kummel, and et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use Ann Oncol 24 2013 618 624
12. S.S. Lo, P.B. Mumby, J. Norton, and et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection J Clin Oncol 28 2010 1671 1676
13. L.R. Henry, A. Stojadinovic, S.M. Swain, and et al. The influence of a gene expression profile on breast cancer decisions J Surg Oncol 99 2009 319 323
14. J.A. Davidson, I. Cromwell, S.L. Ellard, and et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score(R) assay in oestrogen receptor positive node negative breast cancer Eur J Cancer 49 2013 2469 2475
15. A.A. Guth, S. Fineberg, K. Fei, and et al. Utilization of Oncotype DX in an inner city population: race or place? Int J Breast Cancer 2013 2013 653805